Allogene Therapeutics, Inc. (ALLO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Allogene Therapeutics, Inc. (ALLO) Healthcare & Pipeline Overview

Allogene Therapeutics is a clinical-stage biotechnology firm specializing in the development of allogeneic CAR T-cell therapies for cancer. Their pipeline includes candidates targeting lymphomas, multiple myeloma, and acute myeloid leukemia, positioning them in the competitive immuno-oncology market.

What Is the Investment Thesis for ALLO?

Allogene Therapeutics presents a notable research candidate within the immuno-oncology space, driven by its focus on allogeneic CAR T-cell therapies. The company's pipeline, featuring UCART19 and ALLO-501, targets significant unmet needs in hematologic malignancies. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The potential for off-the-shelf CAR T-cell therapies offers a significant advantage over autologous approaches, reducing manufacturing complexity and treatment timelines. However, the company faces risks associated with clinical trial failures, regulatory hurdles, and competition from established players in the cell therapy market. Investors should closely monitor clinical trial data and regulatory milestones to assess the company's progress.

Based on FMP financials and quantitative analysis

ALLO Key Highlights

Market capitalization of $607M reflects investor sentiment regarding Allogene's pipeline and potential.

• Beta of 0.50 indicates lower volatility compared to the broader market, suggesting a more stable investment profile.
• Focus on allogeneic CAR T-cell therapies addresses the limitations of autologous approaches, offering scalability and cost-effectiveness.
• Strategic collaborations with Pfizer, Servier, and Cellectis provide access to resources and expertise, enhancing development capabilities.
• Multiple clinical trials underway across various hematologic malignancies demonstrate a diversified pipeline and potential for multiple product approvals.

Who Are ALLO's Competitors?

ALLO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALLO's Key Strengths?

Proprietary allogeneic CAR T-cell technology platform.

• Strong pipeline of product candidates targeting various hematologic malignancies.
• Strategic collaborations with leading research institutions and pharmaceutical companies.
• Experienced management team with expertise in cell therapy development.

What Are ALLO's Weaknesses?

Clinical stage company with no approved products and no revenue.

• High research and development expenses.
• Dependence on clinical trial success and regulatory approvals.
• Potential for manufacturing challenges and scalability issues.

What Could Drive ALLO Stock Higher?

ALLO catalyst: Data readouts from ongoing Phase 1/2 clinical trials of ALLO-501A in R/R large B-cell lymphoma.

• Initiation of Phase 2 clinical trials for ALLO-715 in R/R multiple myeloma.
• Advancement of preclinical programs targeting solid tumors with allogeneic CAR T-cell therapies.
• Expansion of strategic collaborations with pharmaceutical companies and research institutions.

What Are the Key Risks for ALLO?

Financial-distress signal — its Altman Z-Score of -2.46 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-56.4%) — the business is not currently generating profit on shareholder capital.
• Clinical trial failures or delays could negatively impact the company's pipeline and valuation.
• Regulatory setbacks or changes in reimbursement policies could hinder commercialization efforts.
• Competition from established players in the cell therapy market could limit market share.
• Adverse events or safety concerns associated with CAR T-cell therapy could impact patient adoption.
• Manufacturing challenges or scalability issues could delay product launches and increase costs.

What Are the Growth Opportunities for ALLO?

• Expansion into Solid Tumors: Allogene has the opportunity to extend its allogeneic CAR T-cell technology into solid tumors, addressing a significantly larger patient population. The solid tumor market represents a substantial growth opportunity, with a potential market size exceeding $50 billion. Success in this area would require overcoming challenges related to tumor microenvironment and antigen specificity, but could significantly expand Allogene's market reach. Timeline: Ongoing preclinical research and early-stage clinical trials.
• Strategic Partnerships and Acquisitions: Allogene can pursue strategic partnerships and acquisitions to enhance its technology platform, expand its pipeline, and accelerate commercialization. Collaborations with companies possessing complementary technologies or access to new markets could create synergies and drive growth. The market for cell therapy companies is active, with numerous opportunities for strategic transactions. Timeline: Ongoing, with potential for deals in the next 1-3 years.
• Advancements in Manufacturing Processes: Improving the efficiency and scalability of its allogeneic CAR T-cell manufacturing processes is crucial for reducing costs and increasing accessibility. Innovations in manufacturing technologies, such as closed systems and automation, can drive down production costs and improve product consistency. This will be critical for competing with autologous therapies on price. Timeline: Ongoing process optimization and technology development.
• Expansion of Pipeline with Novel Targets: Allogene can expand its pipeline by identifying and validating new targets for allogeneic CAR T-cell therapy. Targeting novel antigens expressed on cancer cells can open up new therapeutic avenues and address unmet needs in various malignancies. This requires investment in research and development, but can lead to the creation of innovative products with significant market potential. Timeline: Ongoing research and development efforts.
• Geographic Expansion: Expanding into new geographic markets, particularly in Asia and Europe, represents a significant growth opportunity for Allogene. These markets have a growing demand for innovative cancer therapies and offer favorable regulatory environments for cell therapy products. Establishing partnerships with local distributors and healthcare providers can facilitate market entry and accelerate adoption. Timeline: Potential expansion within the next 3-5 years.

What Are ALLO's Competitive Advantages?

• Proprietary allogeneic CAR T-cell technology platform.
• Extensive intellectual property portfolio covering its product candidates and manufacturing processes.
• Strategic collaborations with leading research institutions and pharmaceutical companies.
• Expertise in cell therapy manufacturing and development.

What Does ALLO Do?

Allogene Therapeutics, Inc. is an immuno-oncology company dedicated to developing and commercializing genetically engineered allogeneic T cell therapies for cancer treatment. Founded in 2017 and headquartered in South San Francisco, California, Allogene aims to revolutionize cancer treatment through its innovative approach to cell therapy. The company's lead product candidate, UCART19, is designed to treat pediatric and adult patients with relapsed or refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL). Allogene is also developing ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma, and ALLO-501A, in Phase I/II trials for R/R large B-cell lymphoma or transformed follicular lymphoma. Their pipeline extends to include ALLO-715 for R/R multiple myeloma, ALLO-605 for multiple myeloma, ALLO-647, an anti-CD52 monoclonal antibody, CD70 for renal cell cancer, ALLO-819 for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene has established strategic collaborations with Pfizer Inc., Servier, Cellectis S.A., Notch Therapeutics Inc., and SpringWorks Therapeutics, Inc., as well as The University of Texas MD Anderson Cancer Center, to advance its research and development efforts.

What Products and Services Does ALLO Offer?

• Develops genetically engineered allogeneic T cell therapies for cancer treatment.
• Focuses on off-the-shelf CAR T-cell therapies.
• Manufactures and commercializes UCART19 for R/R CD19 positive B-cell ALL.
• Develops ALLO-501 for R/R non-Hodgkin lymphoma.
• Develops ALLO-501A for R/R large B-cell lymphoma or transformed follicular lymphoma.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Collaborates with leading research institutions and pharmaceutical companies.

How Does ALLO Make Money?

• Develops and patents allogeneic CAR T-cell therapy technologies.
• Out-licenses or co-develops therapies with pharmaceutical partners.
• Generates revenue through milestone payments, royalties, and product sales upon regulatory approval.
• Focuses on hematologic malignancies and solid tumors.

What Industry Does ALLO Operate In?

Allogene Therapeutics operates within the rapidly evolving immuno-oncology market, specifically focusing on cell therapies. The CAR T-cell therapy market is projected to experience substantial growth, driven by increasing prevalence of hematologic malignancies and advancements in genetic engineering. Competition is intense, with established players like Novartis and Gilead Sciences, as well as emerging biotech companies, vying for market share. Allogene's allogeneic approach offers a potential advantage over autologous therapies, addressing scalability and cost challenges. The company's success hinges on demonstrating clinical efficacy and safety, navigating regulatory pathways, and securing reimbursement approvals.

Who Are ALLO's Key Customers?

• Patients with relapsed or refractory hematologic malignancies.
• Hospitals and oncology clinics.
• Pharmaceutical companies through partnerships and collaborations.
• Research institutions for preclinical and clinical research.

Company Profile

Allogene Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Zachary Roberts. ALLO has traded publicly since 2018.

Return on equity for Allogene Therapeutics, Inc. stands at -56.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -43.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -20.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.65 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -33.3%, the inverse of the P/E and a quick read on earnings relative to price.

ALLO Valuation & Market Position

With a $607M market cap, Allogene Therapeutics, Inc. sits in the small-cap segment of the market. Analyst price targets span from $3.85 to $9.00, with a consensus of $6.43. At the current price of $1.76, that implies approximately 265% upside potential. Relative to its peer group, ALLO's quantitative score of 12/100 is below the peer average of 78/100.

Quarterly Financial Performance: Allogene Therapeutics, Inc.

Revenue for Allogene Therapeutics, Inc. came in at $4.6M during Q2 FY2026. The company recorded a net loss of $42.7M, with diluted EPS of $-0.13. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, ALLO averaged $-0.17 in diluted EPS.

Allogene Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -2.46 places it in the distress zone, a signal of elevated financial risk.

Allogene Therapeutics, Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 16.9% above estimates on average.

Over the past six months, Allogene Therapeutics, Inc. insiders filed 16 SEC Form 4 transactions — 6 sales and 10 purchases. On net that is roughly 1.2M shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

ALLO Financials

ALLO Latest News

ALLO Analyst Consensus

ALLO MoonshotScore

Common Questions About ALLO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources